Trials / Completed
CompletedNCT02923206
Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis
Proof-of-Concept Trial on Selective Removal of the Antiangiogenic Factor Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) in Pregnant Women With Preeclampsia Via Apheresis Utilizing the Flt-1 Adsorption Column
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Miltenyi Biomedicine GmbH · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This clinical investigation is a medical device trial to examine the safety and efficacy of TheraSorb sFlt-1 adsorber treatment of pregnant patients with preeclampsia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | TheraSorb sFlt-1 adsorber | Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis. |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2024-08-20
- Completion
- 2025-07-16
- First posted
- 2016-10-04
- Last updated
- 2025-09-30
Locations
4 sites across 2 countries: Germany, United Kingdom
Source: ClinicalTrials.gov record NCT02923206. Inclusion in this directory is not an endorsement.